Retail market volume dropped by 0.4% and amounted to 4.215 billion packs in 2014 according to Russia Retail Audit

At the same time market value grew 12% in rubles and totaled 491.826 billion. Market dollar value amounted to 12.803 billion, which is 8% less than in 2013 due to a significant depreciation of the ruble. Market value numbers are calculated in wholesale prices. Average price per pack of finished pharmaceutical products was 3.90…

Read more

Russian pharmaceutical market grew by 9.3% in 2014 and reached 1.143 trillion rubles

Market volume, however, declined by 3.6% versus 2013 and totaled 5.259 billion packs . Both retail and reimbursement volumes decreased by 4.5% and 7.6%, respectively.

Read more

Thomson Reuters released a market research report on 2015 Drugs to Watch For

A total of eleven blockbusters with 2019 sales forecasted to exceed US $1 billion will enter the market this year (see table below for details). Only six such products were launched in 2014.

Read more

The Ministry of Industry and Trade adopted a plan for substitution of key imported drugs with domestic products

601 drugs are included in the plan according to the order published on Ministry’s website. For many of these drugs the goal was set to reduce imports to 0–10% by 2020. Deputy Minister of Industry and Trade Sergey Tsyb, who is the responsible officer, earlier identified the 90% domestic drug provision in Russia as a strategic goal…

Read more

TOP-25 rating of corporations on the Russian pharmaceutical market by sales value had no major changes in 2014

OTCPharm lost its place in the TOP-10 list, and there are now no Russian corporations among the TOP-10 players. Pharmstandard, however, kept its place in the rating despite a small decrease in the share.

Read more

A common pharmaceutical market in the Eurasian Union may not begin functioning on time

In the course of a recent conference devoted to effective development of markets within the Customs Union multiple experts shared doubts in the ability to develop the required regulatory framework by January 1, 2016. It was suggested that in order to achieve real regulatory harmonization a simple unification of registration, pricing…

Read more

Proposed amendments to the law on federal contractual system offer long-term contracts in exchange for localization of manufacturing sites in Russia

The Ministry for Economic Development together with the Ministry of Finance and the Ministry of Industry and Trade developed a mechanism of seven-year contracts based on agreements with companies to localize manufacturing in Russia. These contracts will allow direct procurement from a single supplier without an auction. These…

Read more

US federal judge declined Amgen’s request to block sales of Novartis’ Zarzio

Zarzio is a Neupogen (filgrastim, Amgen) biosimilar used to prevent infections in patients on chemotherapy. Amgen attempted to delay the launch of its competitor based on Novartis’ failure to meet a regulatory requirement of mandatory inspection of generics manufacturing processes for non-violation of patents still in place (a.k.a.,…

Read more